biocryst is terminating bcx5191 program, page-16

Yes CGT

I dont have a issue with these drugs either. Actually they are exciting. The SUPERBUG is in the news quite often and its good to have a few compounds on the boil in this sector.

We payed $2.70 a share eqivalent for these drugs in BTA shares. Man are they out the backdoor.

So really they were a steal at $3 or $4 million each.

If you did the deal now in BTA shares you would be paying $15 million each.

NIH funding means we are on to something with these. They dont just give the money out.